Chatham-Kent Council Unanimously Endorses AgMedica Bioscience Inc.

For Immediate Release - March 27, 2019

News image

(Chatham-Kent, Ontario) - AgMedica Bioscience Inc. ("AgMedica" or the "Company"), a licensed producer of medicinal cannabis, today confirmed that the municipal council of Chatham-Kent (the “Council”), at its recent Planning Meeting, held a session to discuss zoning issues for cannabis in the municipality. The Council heard staff presentations on cannabis production facilities and invited AgMedica to present to Council. Dr. Trevor Henry, CEO of AgMedica made a comprehensive presentation to Council with forward-looking statements about AgMedica and shared its roots in Chatham-Kent. The presentation focused on the innovation of the Company including its strict adherence to quality growing techniques and its innovation in genomics.

The presentation was made to a packed house and was punctuated by the Company’s corporate video [which is available on its website at]. In a show of absolute support, Council voted on a resolution (herein attached) to support and endorse future support for AgMedica’s growth aspirations, particularly for its facility in Chatham-Kent.

“I’m pleased that Council has endorsed the future of AgMedica in Chatham-Kent,” said Dr. Henry. “I’m particularlypleased that they passed a resolution that endorses to the world that our people and our Company are supportedby our community”. The sole purpose for the Council’s resolution is to enable AgMedica to utilize the formal support of the City to help facilitate the Company’s positive aspirations of extending its reach on a provincial, national and global scale.

About AgMedica Bioscience Inc.

As a licensed producer of medicinal cannabis, AgMedica is dedicated to becoming a global leader in the development and commercialization of cannabis and cannabis-derived products to support the health and wellness of our clients. We aspire to drive the evolution of the cannabis industry by focussing investment on the development and commercialization of differentiated products in the medicinal, health & wellness and pharmaceutical sectors. For further information, please visit our website at

For media or other inquiries, please contact:

AgMedica Bioscience Inc.

Sengkee Ahn, MBA, FEA

Vice President, Investor Relations and International Business Development P: 1-844-247-4633



This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. These risks and uncertainties include, but are not limited to, the availability of further financing, consumer interest in its products, competition, regulation, operational and technological risks, and anticipated and unanticipated costs and delays. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law.


Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.